Overall rank by patents
#26,355
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 3 technology areas, active 2017–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).
The verdict
Gencurix holds 10 US patents across 3 technology areas, rank #26,355 of 50,000 tracked assignees.
Gencurix Inc. has been granted 10 US utility patents between 2017 and 2024, placing Gencurix Inc. at rank #26,355 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 5.3 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a Foreign Corporation, Gencurix Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Gencurix sits between G.i. VIEW Ltd. (10 patents, rank #26,351) and Giken Ltd. (10 patents, rank #26,359) - the closest US assignees by grant volume. The composite Innovation Score of 22.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 3 in the 2015–2019 window, a +133% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Gencurix Inc.'s 5.3 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Gencurix Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
G.I. VIEW LTD.
10 patents
GAUZY LTD.
10 patents
GBRS Group LLC
10 patents
GE Inspection Technologies, LP
10 patents
GENERAL AUTOMATION LAB TECHNOLOGIES INC.
10 patents
GENESIS TECHNOLOGY (USA) INC.
10 patents
GENUS ONCOLOGY, LLC
10 patents
GIKEN LTD.
10 patents
GENCURIX INC.
10 patents
What this shows Gencurix holds 10 patents at rank #26,355, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Gencurix's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
23 Top 89% higher than 11% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 10.0% |
| 2019 | 2 | 20.0% |
| 2020 | 2 | 20.0% |
| 2021 | 1 | 10.0% |
| 2022 | 2 | 20.0% |
| 2023 | 1 | 10.0% |
| 2024 | 1 | 10.0% |
Top 3 of 3 technology areas
Overall rank by patents
#26,355
Across all tracked assignees
22.9 out of 100
How to use this portfolio
Gencurix's 10 grants land it in the top 89% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.